|
Product
(Manufacturer)
|
Source
|
Viral
Inactivation or Purification Procedure
|
Average
Cost
Per Dose ($)a,b |
| Intermediate-purity (SA: 1-10 U/mg protein) | |||
| Humate-P® (Aventis Behring) |
Human
plasma
|
Pasteurization |
3,500
|
| High-purity (SA: 50-1000 U/mg protein) | |||
| Alphanate®
(Alpha Therapeutic) |
Human
plasma
|
Solvent and detergent |
2,975
|
| Koate-HP® (Bayer) |
Human
plasma
|
Solvent and detergent |
3,220
|
| Very-high-(ultra) purity (SA: 3000 U/mg protein) | |||
| Monarc-M® (American Red Cross) |
Human
plasma
|
Solvent and detergent |
N/A
|
| Hemofil-M®
(Baxter Hyland/Immuno) |
Human
plasma
|
Solvent and detergent |
3,325
|
| Monoclate-P® (Aventis Behring) |
Human
plasma
|
Solvent and detergent |
3,325
|
| Recombinate®
(Baxter Hyland/Immuno) |
Recombinant
|
Immunoaffinity chromatography |
4,480
|
| Kogenate FS® (Bayer) |
Recombinant
|
Immunoaffinity chromatography |
4,130
|
| Helixate
FS® (Aventis Behring) |
Recombinant
|
Immunoaffinity chromatography |
4,130
|
| Refacto® (Genetics Institute) |
Recombinant
|
Immunoaffinity chromatography |
4,760
|
| a Cost based on average wholesale price and represents the drug cost to the pharmacy department. b Cost based on the dose required to achieve an AHF level 100% of normal for a 70-kg patient; Abbreviations: SA=specific activity; * Adapted from: Shord SS, Lindley CM. Coagulation products and their uses. Am J Health-Syst Pharm. 2000;57:1403-20 and DiMichele D, Neufeld EJ. Hemophilia: a new approach to an old disease. Hematol Oncol Clin North Am 1998;12:1315-44. | |||